AstraZeneca’s Crestor Targets High Risk Patients, Delivers High Sales
This article was originally published in The Pink Sheet Daily
Executive Summary
Crestor sales grew 47% in the second quarter; entry of generic simvastatin caused some expected “disruption” in the marketplace.